AbbVie receives regulatory approval for plaque psoriasis drug in Japan
AbbVie announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of plaque…
Read More...
Read More...
